News Release

share on google plus
Text size
view with small font size
view with medium font size
view with large font size

July 30, 2015

Kyowa Hakko Kirin Submits Application for Approval in Japan for Brodalumab (KHK4827)

Tokyo, Japan, July 30, 2015 --- Kyowa Hakko Kirin Co., Ltd. (Tokyo: 4151, President and CEO: Nobuo Hanai, "Kyowa Hakko Kirin") announced today that it has filed an application for marketing approval to the Ministry of Health, Labour and Welfare for Brodalumab (code name: KHK4827) which is developed for plaque psoriasis, psoriatic arthritis, pustular psoriasis and psoriatic erythroderma.

Brodalumab is a fully human anti-interleukin-17 receptor antibody. IL-17 is assumed to be involved in autoimmune disease such as psoriasis. Blocking the functions of interleukin-17 may lead to slow the progression of symptoms or to be a therapeutic intervention for such diseases.

The Kyowa Hakko Kirin Group companies strive to contribute to the health and well-being of people around the world by creating new value through the pursuit of advances in life sciences and technologies.

About Psoriasis
Psoriasis is a chronic skin disorder. Typical symptoms include systemic erythema with clearly demarcated lesions, induration and hyperplasia inducing silver white plaques on skin. Itching, inflammatory arthritis and abnormality in nail morphology may also manifest.

About Interleukin-17
Interleukin-17 is a protein produced in the body, mostly in the activated T lymphocytes. Overexpression of interleukin-17 turns on the immune system to attack itself, though the system is originally supposed to work for host-defense by removing foreign pathogens.

To Page Top